Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS)-Reference-Cited by-同舟云学术

Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS)

Published:2021-02-10 Issue:2 Volume:8 Page:131-140
ISSN:2199-1154
Container-title:Drugs - Real World Outcomes
language:en
Short-container-title:Drugs - Real World Outcomes

Author:

Yuan Jing,Li Minghui,Yu Yiqun,Lee Tai-Ying,Lv Gang,Han Bing,Xiang Xiaoqiang,Lu Z. Kevin

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40801-021-00229-8.pdf

Reference28 articles.

1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. Available from: https://wwwwhoint/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. Accessed 20 Jan 2021.

2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–4.

3. Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145.

4. Health NIo. Coronavirus disease 2019 (COVID-19) treatment guidelines 2020. https://www.covid19treatmentguidelines.nih.gov/whats-new/. Accessed 15 Apr 2020.

5. US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of Covid-19 in certain hospitalized patients. 2020. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization. Accessed 15 Apr 2020.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Introductory Chapter: Current Perspective of COVID-19 Drugs;COVID-19 Drug Development - Recent Advances, New Perspectives and Applications;2022-12-07

2. Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19;Pharmaceuticals;2022-11-26

3. Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS);Drugs - Real World Outcomes;2022-04-06

4. The assessment of similarity vectors of fingerprint and UMLS in adverse drug reaction prediction;2021-11-16

5. COVID-19 TEDAVİSİNDE İLAÇ-İLAÇ ETKİLEŞİMLERİNİN FARMAKOKİNETİK AÇIDAN DEĞERLENDİRİLMESİ;Ankara Universitesi Eczacilik Fakultesi Dergisi;2021-05-25